Artemis Strategic Investment and Danam Health today announced a definitive merger agreement at an expected combined pro forma enterprise value of approximately $200 million.
If approved, upon closing Danam Health Holdings stock and warrants are expected to be listed on the Nasdaq.
The target is a health services technology and pharmaceutical distribution company with a healthcare ecosystem model designed to bring efficiency to the issuance of prescriptions and promote medication compliance. Danam said it is poised to disrupt the pharmaceutical market through its business-to-business-to-consumer portfolio of integrated companies offering a health ecosystem aimed at increasing market access for pharmaceutical products by leveraging key market insights and intelligence. Danam’s four pillars include improving access to medications, fostering an environment of transparent prescription pricing, reducing costs across the healthcare system, and improving patient medication adherence to generate positive outcomes in a patient-centric model.
The transaction is expected to be completed in the fourth quarter.
Nelson Mullins Riley & Scarborough is legal counsel for Danam, and Ellenoff Grossman & Schole is serving as legal counsel for Artemis. Read more.
